In a major breakthrough for India’s indigenous potential COVID Coronavirus vaccine candidate, its developer Zydus Cadila has received nod from Mexico’s regulatory authority Cofepris to conduct human trials in that country. The company has revealed that the human trials will be “an open-label, randomized, comparator-controlled study… to evaluate safety, efficacy and tolerability in patients with COVID-19”. In another development, India’s COVAXIN produced by ICMR, Bharat Biotech, and National Institute of Virology, Pune have started its human trials for the country’s first indigenous COVID Coronavirus vaccine.
Around the world, human trials of potential COVID Coronavirus vaccine candidates developed by US’ Moderna, and UK’s Oxford-AstraZeneca have shown positive results so far.
University of Oxford researchers have revealed that they might have a breakthrough in their endeavour to produce a COVID-19 vaccine. The announcement has come after the University of Oxford team discovered that the jab could provide “double protection” against the deadly coronavirus following early-stage human trials. The human trials of Oxford-AstraZeneca showed that the dose of vaccine has successfully managed to produce both antibodies and “killer T-cells” in the receiver’s body. The results are promising because separate studies have indicated that antibodies may fade away within months while T-cells can stay in circulation for years.
The vaccine candidate has entered the Phase III Human trials. While Phase 1 trial of the potential coronavirus vaccine has shown promising results, the complete data will be published on July 20.
US-based Moderna has also been working on a potential coronavirus vaccine candidate known as mRNA-1273. The phase I trials of Moderna began on March 16 and Moderna was the first organization to commence the clinical trial of the potential coronavirus vaccine candidate. An interim analysis has revealed that an immune response has been generated in participants of phase I clinical trials, as per a report published in the New England Journal of Medicine. Moderna will begin its Phase III trials on July 27.
World Health Organization (WHO) has revealed that more than 150 potential vaccines for coronavirus are at different stages of development. So, around 23 vaccines have managed to reach the human trials phase.